Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 476-486

  Anderson, Garnet L ^a   Chlebowski, Rowan T ^b   Aragaki, Aaron K ^a   Kuller, Lewis H ^c   Manson, JoAnn E ^d   Gass, Margery ^e   Bluhm, Elizabeth ^f   Connelly, Stephanie ^g   Hubbell, F Allan ^h   Lane, Dorothy ⁱ   Martin, Lisa ^j   Ockene, Judith ^k   Rohan, Thomas ^l   Schenken, Robert ^m   Wactawski Wende, Jean ⁿ  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e North American Menopause Society   (United States)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k UNIVERSITY OF MASSACHUSETTS   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

AGED; BREAST NEOPLASMS; COHORT STUDIES; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; WOMEN'S HEALTH;

EID: 84860474009     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70075-X     Document Type: Article

References (57)

1. Yager JD, Davidson NE Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282.
2. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589-1593.
3. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997, 350:1047-1059. Collaborative Group on Hormonal Factors in Breast Cancer.
4. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006, 166:1027-1032.
5. Beral V, Reeves G, Bull D, Green J Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011, 103:296-305. the Million Women Study Collaborators.
6. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002, 100:1148-1158.
7. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003, 289:3254-3263.
8. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2008, 17:3150-3160.
9. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. Million Women Study Collaborators.
10. Rosenberg LU, Granath F, Dickman PW, et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 2008, 10:R78.
11. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999, 91:264-270.
12. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996, 7:449-457.
13. Chen W, Petitti DB, Geiger AM Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer 2005, 93:392-398.
14. Newcomb PA, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:864-871.
15. Norman SA, Weber AL, Localio AR, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010, 19:440-447.
16. Reding KW, Doody DR, McTiernan A, et al. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat 2011, 126:749-761.
17. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657. the WHI Investigators.
18. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712. the Women's Health Initiative Steering Committee.
19. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy. JAMA 2011, 305:1305-1314.
20. Surveillance, epidemiology and end results program National Cancer Institute, (accessed April 11, 2011). http://seer.cancer.gov/.
21. Robins JM, Finkelstein DM Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000, 56:779-788.
22. Chlebowski RT, Anderson GL, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 2010, 28:2690-2697.
23. Kerlikowske K, Miglioretti DL Effects of estrogen-only treatment in postmenopausal women. JAMA 2004, 292:684-685.
24. Greendale GA, Judd HL The menopause: health implications and clinical management. J Am Geriatr Soc 1993, 41:426-436.
25. Iversen L, Delaney EK, Hannaford PC, Black C Menopause-related workload in general practice 1996-2005: a retrospective study in the UK. Fam Pract 2010, 27:499-506.
26. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG 2002, 109:1319-1330. Million Women Study Collaborators.
27. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998, 19:61-109. The Women's Health Initiative Study Group.
28. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008, 167:1407-1415.
29. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008, 167:1207-1216.
30. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253. the WHI Investigators.
31. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587. the WHI Investigators.
32. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692. the WHI Investigators.
33. Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009, 27:3235-3258. the American Society of Clinical Oncology.
34. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391. the NCIC CTG MAP.3 study investigators.
35. Cook NR, Rosner BA, Hankinson SE, Colditz GA Mammographic screening and risk factors for breast cancer. Am J Epidemiol 2009, 170:1422-1432.
36. Joffe MM, Byrne C, Colditz GA Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology 2001, 12:429-438.
37. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005, 34:405-412.
38. Waller M, Moss S, Watson J, Møller H The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev 2007, 16:2257-2261.
39. Weiss NS Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol 2003, 157:957-961.
40. Joffe MM Invited commentary: screening as a nuisance variable in cancer epidemiology: methodological considerations. Am J Epidemiol 2003, 157:962-964.
41. McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009, 27:6135-6143.
42. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000, 6:2028-2036.
43. Jordan VC The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death?. J Clin Oncol 2008, 26:3073-3082.
44. Lewis-Wambi JS, Jordan VC Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. Breast Cancer Res 2009, 11:206.
45. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009, 302:774-780.
46. Dunbier AK, Martin LA, Dowsett M New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol 2011, 340:137-141.
47. Song RX, Mor G, Naftolin F, et al. Effect of long term estrogen deprivation on apoptotic responses of breast cancer cells to 17B-estradiol. J Natl Cancer Inst 2001, 93:1414-1423.
48. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005, 97:1746-1759.
49. Liu H, Lee ES, Gajdos C, et al. Apoptosis action of 17 beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2008, 95:1586-1597.
50. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
51. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706. the National Surgical Adjuvant Breast and Bowel Project.
52. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009, 170:12-23.
53. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011, 29:2327-2333.
54. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796. the American Society of Clinical Oncology.
55. Kanematsu M, Morimoto M, Honda J, et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 2011, 11:436.
56. Chlebowski RT, Anderson GL, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008, 168:370-377.
57. Pitteri SJ, Hanash SM, Aragaki A, et al. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009, 1:121.